Event in Progress:
Discover the latest content that has just been published on Research Tree
9M update: sales were down 11% with the EBITDA margin contracting to 2.8%. The net loss for the period stood at €-63m. By region, Southern Europe recorded a sales contraction of 8% and the EBITDA margin was at 4.6% (-60bp). Northern Europe’s sales were down 14%, whereas the EBITDA margin stood at 1.9%. North America recorded -12% in sales with the EBITDA margin at 5% (vs. 17% a year earlier). The International businesses’ revenues were down 6% and the margin stood at 11.2% (-110bp).
Companies: Deoleo, S.A.
AlphaValue
H1 update: sales were down 9.4%, whereas EBITDA contracted by 35.5% to 4.2%. The net loss for the period stood at €-49m (impacted by the impairment of intangible assets of €37.4m and the EBITDA contraction). By region, Southern Europe recorded a 5% contraction in sales, whereas the EBITDA margin dropped by 120bp. Northern Europe recorded 19% in sales and the EBITDA margin progressed by 70bp. North America was very weak with sales down 8% and a margin contraction to 7.5% (vs. 19.5% yoy). The Int
9M update: sales were down 1.2% with the EBITDA margin standing at 5.2%. The net loss for the period stood at €-5m. By region, Southern Europe recorded +2% sales progression and the EBITDA margin at 5.2%. Northern Europe continues its weak performance with sales down 19% and an EBITDA margin contraction to -0.9%. North America recorded -5% in sales with the margin at 17%. The International businesses’ revenues were up +3% and the margin stood at 12.4%. The increase in general restructuring cost
H1 update: sales are up 1.5%, whereas the EBITDA stood at 5.9%. The net loss for period stood at €-5m. By region, Southern Europe recorded a good +3.5% sales progression and EBITDA margin expansion to 5.6%. Northern Europe had a very weak performance with sales -13% and an EBITDA margin contraction to 0.7%. North America performed well with sales -3.9% but a margin progression of 240bp to 19.5%. The International business also ran well with revenues up +6.8% and margin expansion to 13.9%. The i
Deoleo’s H1 update: Vegetable oil sales were down 17.5%, whereas the EBITDA margin contracted to 5% (vs. 5.7% last year). The net loss for the period widened to -€19.8m (vs. -€9.8m in Q1 16). Net debt stood at €543.5m vs. €548.4m in Q1.
Deoleo released its Q1 update. Sales were down 16%, whereas the EBITDA margin contracted 70bp to 5.7%. The loss for the period stood at €9.8m. Net debt grew by +4.4% to €548.4m due to the seasonal effect of the crop campaign.
Deoleo recorded another very poor quarter and the full-year results came in below our expectations. Although FY net sales were up +5.7%, the EBITDA margin contracted by 65% to 2.5%. The company’s performance continues to be impacted by the high prices of raw materials in Spain, coupled with promotional pressures in the market. On a FY basis, the Spanish unit recorded a slump in sales of -17.6% and a negative margin of 5.9% (vs. 5.04% in FY14). The group expects EBITDA to be positive as from th
Deoleo released its H1 results. Sales were up by 12.3%. Revenue by unit: North America (+18.6%), International markets (+8%), Southern Europe (14.95%) and Spain (+18.65%). EBITDA halved (€22.7m vs. €41.88m yoy) and the EBITDA margin was down by 610bp. EBITDA by unit: North America (+38.1%, +210bp), International markets (-16.27%, -280bp), Southern Europe (-48.22%, -420bp) and Spain (-58.77%, -410bp). Net debt rose to €542m (due to higher raw material prices). The company reported a net lo
Research Tree provides access to ongoing research coverage, media content and regulatory news on Deoleo, S.A.. We currently have 9 research reports from 2 professional analysts.
FY23 results are much in line with overall expectations, helped by a much stronger H2 production and higher purchases of independent crops helping to fill the group’s rising mill capacity. A marginally higher than expected average CPO price mill-gate price of $729/tonne drove the revenue outperformance, but the change in production mix impacted gross margins while slightly higher than anticipated interest, tax and minority charges resulted in EBIT, PBT (Adj.) and EPS (Adj.) just below our foreca
Companies: M.P. Evans Group PLC
Cavendish
The second full year of Greggs’ five-year growth plan to double revenue by FY26 should be marked down as very successful, especially so given the challenging external environment. Unlike many consumer-facing companies, high selling price inflation was accompanied by volume growth, leading to good market share gains. The consumer is responding well to new initiatives to grow revenue in new dayparts and digital channels. Profitability was well-managed with better recovery of input cost inflation t
Companies: Greggs plc
Edison
Companies: Anpario plc
Shore Capital
Companies: CLA VAST CMET SRB CEY TGR
SP Angel
Companies: RNWH QED GRG PEBB FDM OTB LAND BOO
Companies: MPE ING EXR
Ocean Harvest Technology (OHT), based in the UK, produces animal feed additives products using a composite of blended seaweed. Its patented products have been shown to enhance growth rates in livestock, increase feed efficiency and improve egg quality and quantity for laying poultry. As OHT operates in an attractive market, there is significant potential for its proprietary technology to drive volume growth as awareness of its product benefits increases, along with improving financials.
Companies: Ocean Harvest Technology Group Plc
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
20th March 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment object
Companies: CTL EKF IQG ANP SML VRS EQLS POLB
Hybridan
Companies: Greencore Group Plc
Companies: Genus plc
Liberum
10th October 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje
Companies: TXG GFM TGIF TXG ENSI TIDE IGP IGE NTQ CYAN REAT
Companies: Anpario plc (ANP:LON)GSK plc (GSK:LON)
Share: